RCn: a new class of micellar antitumor drugs with specific affinity for tumor cells membranes and ability to behave as nanocarriers for other bioactive molecules
- Detailed Technology Description
- Recentgenerations of anti-cancer therapies provide more effective treatment withreduction of toxicity by two approaches: the use of a new drug with specifictumor-targeting properties, and the use of drug-loaded nanosized carriers. RCn moleculesrepresent a novel class of compounds that demonstrate effective anti-tumorproperties and limited toxicity as both a tumor-targeting drug and a micellecarrier.
- Countries
- Not Available
- Application No.
- None
- *Abstract
-
None
- *Inquiry
- Andrew CorrisThe Research Institute atNationwide Children's HospitalOffice of TechnologyCommercialization700 Children'sDrive Columbus OH 43205T: 614 355-1604 F: 614722-2716Andrew.Corris@nationwidechildrens.org
- *IP Issue Date
- None
- *IP Type
- Other Patent
- Country/Region
- USA
For more information, please click Here
